Abstract -Preeclampsia has been shown to be associated with changes in cerebral structure and cognitive function later in life. Nf (neurofilaments) are specific scaffolding proteins of neurons, and their quantification in serum has been proposed as a biomarker for neuroaxonal injury. We performed a prospective, longitudinal, single-center study at the University Hospital of Basel to determine serum Nf concentrations in pregnant women with singleton pregnancies and with high risk of preeclampsia or with early signs of preeclampsia. Enrollment started at 21 weeks of gestation, followed up with multiple visits until delivery. Sixty out of 197 women developed preeclampsia (30.5%). NfL (Nf light chain) was measured with a highly sensitive single molecule array (Simoa) assay, in addition to the established preeclampsia markers sFlt-1 (soluble fms-like tyrosine kinase-1) and PlGF (placental growth factor). The most important independent predictors of NfL were maternal age, number of pregnancies, and proteinuria. NfL levels increased during pregnancy and were significantly higher in women developing preeclampsia. The discriminatory accuracy of NfL, PlGF, and sFlt-1 in receiver operating characteristic curves analysis (area under the curve) of the overall group was 0.68, 0.81, and 0.84, respectively, and in women older than 36 years 0.7, 0.62, and 0.79, respectively. We conclude that increased axonal injury serum marker NfL predicts preeclampsia particularly in older women, with an accuracy similar to the established angiogenic factors. NfL may serve as an early indicator of preeclampsia-induced changes in cerebral structure and may help to stratify disease management.
W orldwide hypertensive disorders of pregnancy are a serious health issue for women and their children, accounting for 12% of maternal deaths. In high-income countries, it affects between 2% and 8% of all pregnancies. 1 The most important hypertensive disorder in pregnancy is preeclampsia. 2 Preeclampsia is a pregnancy-specific syndrome defined by the new onset of hypertension after 20 weeks of gestation and by proteinuria. 2, 3 Additional symptoms frequently complicate preeclampsia such as neurological symptoms, epigastric pain with nausea or vomiting, thrombocytopenia, and abnormal liver enzymes. This complication of preeclampsia is known as HELLP syndrome, with H standing for hemolysis, EL for elevated liver enzyme levels, and LP for low platelet levels. 4 Pregnant women have an increased risk of developing preeclampsia if there is, for example, and just to mention the most common, a previous history of preeclampsia, multiple pregnancies, preexisting diabetes mellitus, nulliparity, high body mass index before pregnancy, or maternal age ≥40 years. 5 Over the last decade, a variety of translational biomarker studies improved fundamentally our understanding and diagnosis of preeclampsia mainly addressing the cardiovascular dysfunction of the disease. 6, 7 Preeclampsia is a heterogeneous, multi-system disorder and can impair the central nervous system (CNS). 8 Certain neurological symptoms may precede the onset of seizures, such as persistent headaches, blurred vision, photophobia, and altered mental status. 9 Furthermore, preeclampsia may cause long-term cognitive changes and increased lifetime risk of cerebrovascular stroke. 10 Preeclampsia is associated with long-term cerebral white and gray matter changes and cognitive impairment. 11, 12 Nf (neurofilaments) are highly specific major scaffolding proteins of neurons consisting of 4 subunits: the triplet of NfL (Nf light), Nf medium, and NfH (Nf heavy) chains and α-internexin in the CNS, or peripherin in the peripheral nervous system. 13 Disruption of the axonal cell membrane because of acute or chronic neuronal damage releases Nf into the interstitial fluid and eventually to the cerebrospinal fluid and the blood compartment. 14, 15 Significantly increased serum concentrations of Nf were found after acute brain injury such as ischemic or hemorrhagic stroke, traumatic brain injury, cervical artery dissection, and spinal cord injury compared with healthy individuals, [16] [17] [18] [19] and also in patients with multiple sclerosis and various neurodegenerative diseases. 20, 21 Recent advances using highly sensitive Simoa technology improved the detection of NfL particularly in peripheral blood making NfL a promising and an easily accessible biomarker for neuroaxonal injury. [22] [23] [24] [25] The aim of this study was to (1) measure serum NfL concentrations at multiple visits in a cohort of pregnant women with high risk of developing preeclampsia or with early signs of preeclampsia, (2) investigate clinical factors that influence serum NfL concentrations, and (3) study the prognostic value of NfL compared with the established angiogenic factors sFlt-1 (soluble fms-like tyrosine kinase-1) and PlGF (placental growth factor) in predicting preeclampsia.
Materials and Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
This prospective, observational study was conducted at the University Hospital of Basel between 2011 and 2015. The Ethics Committee of Northwestern Switzerland (PB_2016-02490) approved the study protocol, and written informed consent was obtained from all participating women.
Women >18 years of age with a singleton pregnancy were included if they presented with at least 1 risk factor for preeclampsia: nulliparous obese women with body mass index >26.1 kg/m 2 , nulliparous women >40 years of age, preexisting diabetes mellitus, essential hypertension or renal disease, pregnancy-induced hypertension, gestational diabetes mellitus, uteroplacental dysfunction, previous preeclampsia, eclampsia or HELLP, thrombophilia, antiphospholipid antibodies, family history of preeclampsia, or eclampsia or HELLP in first-line relatives. Women with hypertension (systolic blood pressure [BP] >140 and diastolic BP >90 mm Hg) and proteinuria (>1+ in dipstick which corresponds to a protein concentration ≥30 mg/ dL protein in spot urine) were also included as these clinical findings are associated with increased risk of preeclampsia. Exclusion criteria were chromosomal aberrations, fetal malformations, abortion, or stillbirth <22 weeks of gestation. All eligible women were enrolled into the study during antenatal visits starting with first visit at 21 to 24 weeks of gestation (visit 0) or during hospitalization at 21 weeks of gestation or later. Thus, a rolling enrollment was allowed. Women were followed up every 2 to 4 weeks with study visits including recording of demographic characteristics, medical history, clinical examinations, and drawing blood for biomarker analyses (sFlt-1, PlGF, and NfL). The study comprised up to 5 visits, visit 0 at 21 to 24 weeks, visit 1 at 25 to 29, visit 2 at 29 to 32, visit 3 at 33 to 36, and visit 4 at 37 to 40 weeks of gestation. Women with symptoms of preeclampsia and those at increased risk of preeclampsia and suggestive clinical findings were controlled clinically and biochemically from minimum every day to maximum every 14 days dependent on their clinical condition until delivery. Results of biomarker analyses were not available until the end of study, hence did not influence clinical management and treatment.
Diagnostic Criteria for Hypertension-Associated Diseases in Pregnancy
Diagnostic criteria for preeclampsia were new-onset systolic BP ≥140 mm Hg and diastolic BP ≥90 mm Hg measured on 2 occasions at least 4 hours apart but within 1 week, and new onset of proteinuria with ≥300 mg/24 h urine protein collection or ≥2+ in dipstick >20 weeks of gestation.
2 Diagnostic criteria for each preeclampsia-related disorder were based on international guidelines (Table S1 in the online-only Data Supplement). 2 Neurological symptoms included headache, confusion, and visual disturbances. 26 
Sample Preparation and Assessment of PlGF, sFlt-1, and NfL
Serum samples were collected and processed according to a standard operating procedure, defining venipuncture of the antecubital vein, subsequent sample transfer to the central laboratory service, centrifugation, preparation of aliquots, and storage at −80°C until batch-wise analysis. All samples used in the current analysis had not previously been thawed. Researchers performing the assays were blinded to the patients' clinical information and pregnancy outcome.
Maternal serum levels of sFlt-1 and PlGF were measured using Roche Elecsys assays on the electrochemiluminescence immunoassay platforms, Modular E170 (Roche Diagnostics) until October 2014 and Cobas 6000 (Roche Diagnostics) from November 2014 until the end of the study. The within-run coefficient of variation for quality control samples was <1.5% for the sFlt-1 and <0.9% for the PlGF assay on Modular E170. Between-run coefficients of variation are 2.5% to 3.9% for the sFlt-1 and 2.7% to 3.7% for the PlGF assay on Modular E170 and 1.2% to 2.3% for the sFlt-1 and 1.7% to 2.0% for the PlGF assay on Cobas 6000.
The concentration of NfL was determined using a Simoa assay, which was established using the NF-light assay ELISA kit from UmanDiagnostics (Umeå, Sweden), transferred onto the Simoa platform with a homebrew kit (Quanterix Corp, Boston, MA), and has been described in detail by our group elsewhere.
25 Calibrators (neat) and serum samples (1:4 dilution) were measured in duplicates. Bovine lyophilized NfL was obtained from UmanDiagnostics. Calibrators ranged from 0 to 2000 pg/mL. Batch prepared calibrators were stored at −80°C. Intra-and interassay variabilities of the assay were <10%. Repeated measuring was performed for the few samples with intra-assay coefficients of variation >20%.
Statistical Analysis
In terms of descriptive statistics, tests for difference between patients with and without preeclampsia were performed using the Student t test for normally distributed continuous variables, with the MannWhitney-Wilcoxon test for non-normally distributed continuous variables, or with Pearson χ 2 test for dichotomous variables. Univariate and multivariate-adjusted logistic models were fitted with final preeclampsia diagnosis as dependent variable with baseline (visit 3) categorical variables, ethnicity (4 levels), number of pregnancies (8 levels), parity (5 levels), smoking status (3 levels), neurological symptoms (yes/no) and proteinuria (yes/no) and covariates age, body mass index, systolic BP, PlGF, and sFlt-1 as independent variables.
The predictive power of the model was validated using cross-validation. Forest plots were used to compare the area under the curve (AUC) from the resulting plots. receiver operating characteristic curves shown are from univariate models. 27 A post hoc subgroup analysis was performed by dividing patients by age according to a specific cutoff point; results are shown for the groups based on the median age (36 years, groups being 18-36 and 37-49).
To investigate NfL effects in more detail, an adjusted linear mixedeffects model was fitted with NfL as dependent variable and the above-mentioned variables as fixed-effect regressors with random intercept and slope effects for the visit.
All analyses were conducted with the statistical package R (R Foundation for Statistical Computing), and a value <0.05 was considered statistically significant. Further information is provided in the online-only Data Supplement.
Results
Between September 1, 2011, and June 30, 2015, a total of 236 women between the ages of 18 to 49 years were recruited for the study. Thirty-nine women dropped out because of nonavailability of serum samples for this study. Finally, a total of 197 women were included, 85% were White, 10% Asian, 2% Black, and 3% other or missing. Sixty women developed preeclampsia (30.5%) of whom 30 women (50%) developed early-onset preeclampsia (before 34 weeks of gestation). The triplet of serum biomarkers PlGF, sFlt-1, and NfL was measured in 410 serum samples of these 197 women; thus, on average, there were 2 visits per women. Table 1 summarizes the baseline characteristics with P values for the comparison of patients with and without preeclampsia during the study.
In the mixed-effects linear model with NfL as a dependent variable, preeclampsia status (P<0.0001), maternal age (P<0.001), number of pregnancies (P<0.001), and proteinuria (P<0.001) had a significant and independent influence on NfL, whereas, unexpectedly, systolic BP and neurological symptoms were not identified as significant factors influencing serum NfL concentrations (Tables S3). NfL levels were higher in women with preeclampsia when compared with women not developing preeclampsia (controls; Figure 1 , upper; Table S2 ). NfL increased with increasing maternal age with a steeper increase in women with preeclampsia compared with controls ( Figure 1, lower) .
In univariate logistic regression analyses, increased levels of NfL and sFlt-1 were associated with an increased risk of preeclampsia, whereas increased PlGF levels showed a reduced risk for preeclampsia (Table 2 with preeclampsia as dependent variable). In addition, criteria that lead to the diagnosis of preeclampsia (systolic BP and proteinuria) and the associated neurological symptoms were also significant factors for increasing the risk of preeclampsia. After adjusting for various factors, NfL remained predictive for preeclampsia (Table 2) .
Receiver operating characteristic curve analysis revealed that in the overall group, NfL (AUC, 0.68; 95% confidence interval [CI], 0.60-0.77) was not superior to the established biomarkers sFlt-1 (AUC, 0.84; 95% CI, 0.77-0.91) and PlGF (AUC, 0.81; 95% CI, 0.74, 0.87) to predict preeclampsia (Figure 2, left) . The predictive ability of NfL enhanced in the age group >36 years (NfL: AUC, 0.7; 95% CI, 0.5-0. 
Discussion
NfL is a highly specific structural protein of neurons. Elevated serum levels of NfL are increasingly recognized as measures of acute or chronic neuroaxonal damage. In this prospective longitudinal study, enrolling pregnant women at increased risk to develop preeclampsia or with early signs of preeclampsia after 20 weeks of gestation, we measured NfL levels together with the established preeclampsia markers sFlt-1 and PlGF at multiple visits until delivery. The major findings are (1) women developing preeclampsia have elevated levels of NfL compared with women without preeclampsia, (2) there is a positive correlation of NfL with maternal age, and (3) NfL is of predictive value for preeclampsia especially in women >36 years.
Cerebral autoregulation confers constant cerebral blood flow over a wide range of systemic BP ranging from 60 to 150 mm Hg. 28 Outside this range, autoregulation is lost and significant brain tissue damage can occur because of hyperperfusion, blood-brain barrier (BBB) disruption, and vasogenic edema formation. 29 The BBB is the interface between the circulating blood and the brain and functions as gatekeeper for substances between both blood and brain. 30 Women experiencing preeclampsia are at increased risk for hampered autoregulation and subsequent cerebral edema because of severe hypertension. [31] [32] [33] In addition, in preeclampsia, a large variety of circulating factors is increased, of which at least some directly impair BBB integrity. 34, 35 Brain edema identified by magnetic resonance imaging in patients with preeclampsia was associated with BBB disruption and abnormalities in endothelial damage markers but not with hypertension level. 36 In our multivariate linear regression analyses performed with NfL as dependent variable, neither systolic BP nor proteinuria were significant predictors of NfL. However, maternal age and sFlt-1 were factors, indicating that distinct changes in this multi-system disorder are stronger predictors of NfL than the clinical hallmarks hypertension and proteinuria.
Few studies investigated different peripheral biomarkers of CNS injury in preeclampsia and reported increased values of the calcium-binding protein S100B and the neuron-specific enolase, [37] [38] [39] [40] supporting the notion of possible cerebrovascular dysfunction and BBB disruption in preeclampsia. 41 In our prospective cohort, no women developed severe cerebral complications such as seizures or stroke. Thus, the broad elevation of NfL in women with preeclampsia may indicate subclinical cerebral involvement. Odds ratios with 95% confidence intervals (CIs) from fitting univariate (left) and multivariate-adjusted logistic regression models (right) with dependent variable final preeclampsia status. BMI indicates body mass index; nE, not estimated in final model; NfL, neurofilaments light chain; NS, not significant at the 5% level; PlGF, placental growth factor; and sFlt-1, soluble fms-like tyrosine kinase-1 *Final adjusted model determined via stepwise backwards selection using Akaike and Bayesian information criteria; PlGF and sFlt-1 not considered as they are existing biomarkers; BP (blood pressure) and dipstick not included as these are currently used diagnostics. Only those covariates found to be significant risk factors in the univariate analysis were carried forward to the multivariate analysis.
In addition to the longitudinal study design, a further strength of our study is the measurement of sFlt-1 and PlGF in all samples in parallel to NfL. Both sFlt-1 and PlGF have gained great attention in recent years as highly sensitive and specific markers for the assessment of women with suspected preeclampsia. 42 On the basis of the whole cohort, we found high AUC values for predicting preeclampsia of sFlt-1 and PlGF and a lower value for NfL (Figure 2, left) . When considering the effect of aging on NfL and dividing the study population into 2 groups based on the median of maternal age, the AUC of NfL improved compared with sFlt-1 and PlGF (Figure 2, right) . The higher predictive value of NfL in women >36 years is in line with the findings from the mixed-linear effect model fitted with NfL as dependent variable. Both modeling approaches seem to indicate that NfL increases with aging in women with preeclampsia stronger than in the control group.
An association of NfL with age in healthy controls has been reported consistently, [43] [44] [45] [46] [47] [48] whereas it is typically absent in established multiple sclerosis (relapsing-remitting multiple sclerosis, 20, 47, 49 secondary progressive multiple sclerosis, 50 and primary progressive multiple sclerosis 47 ) and in patients with a clinically isolated syndrome. 46, 47, 49 The finding that Nf levels in serum are in close correlation with those in cerebrospinal fluid marks a breakthrough for its routine use in intraindividual longitudinal assessments of multiple sclerosis and in primary neurodegenerative disorders like amyotrophic lateral sclerosis and frontotemporal dementia. 25, [51] [52] [53] [54] [55] [56] [57] The high association between these 2 compartments is the prerequisite to support the assumption that blood NfL measurements indeed reflect CNS neuroaxonal injury. 24 With the advent of the single molecule array (Simoa) technology as a digital immunoassay, the sensitivity has significantly improved and allows the reliable and accurate quantification of serum NfL levels in healthy controls. 22, [58] [59] [60] On the basis of this analytic platform, the high correlation for NfL levels between the cerebrospinal fluid and blood compartment has been confirmed in multiple sclerosis, 25 as well as in other diseases like HIV infection, 60 progressive supranuclear palsy, 61 boxers after bout, 24 mild cognitive impairment/Alzheimer's disease, and cognitively normal controls. 62 In our study, only pregnant women at increased risk of developing preeclampsia or with early signs of preeclampsia have been enrolled. Thus, conclusions drawn on the controls in this study must be interpreted carefully, especially with respect to healthy pregnancies, and we would recommend additional investigations on NfL in this regard. In fact, there is a lack of published information on NfL levels for healthy women with or without pregnancy. A further limitation of our study is the limited number of longitudinal measurements per women. On average, we collected 2 samples per study participant, and there was a considerable variability in the number of visits attended by the women, as highlighted in Figure S1 which describes the trajectories of NfL values over all 5 visits.
We suggest that further studies investigate these baseline values, stratified by age group, to test our 2 main hypothesis from the study, namely, that age plays a role of the rise of NfL levels, and second, that having preeclampsia may affect BBB and CNS tissue integrity.
Perspectives
Our results show that NfL levels are increased in pregnant women at high risk of preeclampsia or with early signs of preeclampsia in comparison to those who did not and that NfL may have predictive value for preeclampsia particularly in older pregnant women. Our study is expected to motivate further investigations as to examine closely the association of NfL levels with cerebral symptoms and to combine NfL measurements with magnetic resonance imaging investigations. This would potentially pave the way to establish NfL as an early indicator of preeclampsia-induced neuroaxonal injury and to use NfL as an adjunct in preeclampsia management similar to NfL perspectives in neurodegenerative diseases. 
